The treatment of differentiated thyroid cancer in children: Emphasis on surgical approach and radioactive iodine therapy

Endocrine Reviews

Volumn 32, Issue 6, 2011, Pages 798-826

  Rivkees, Scott A ^a   Mazzaferri, Ernest L ^b,c   Verburg, Frederik A ^d   Reiners, Christoph ^d   Luster, Markus ^e   Breuer, Christopher K ^a   Dinauer, Catherine A ^a   Udelsman, Robert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CALCITONIN; IODINE 131; LEVOTHYROXINE; PROTEIN RET; RECOMBINANT THYROTROPIN; THYROXINE;

ASPIRATION BIOPSY; BYSTANDER EFFECT; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHILD; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; DOSIMETRY; ECHOGRAPHY; FOLLOW UP; FREE THYROXINE INDEX; GASTRITIS; GENE MUTATION; GENE REARRANGEMENT; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; LUNG FIBROSIS; LYMPH NODE DISSECTION; MINIMAL RESIDUAL DISEASE; NAUSEA AND VOMITING; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RADIATION HAZARD; RADIOACTIVITY; RADIOISOTOPE THERAPY; RECURRENCE RISK; REPRODUCTIVE TOXICITY; REVIEW; RISK REDUCTION; SECOND CANCER; SUBTOTAL THYROIDECTOMY; SURGICAL APPROACH; SURVIVAL TIME; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

ADOLESCENT; CHILD; COMBINED MODALITY THERAPY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; LYMPH NODE EXCISION; NEOPLASM GRADING; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RECURRENCE; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 83755186707     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2011-0011     Document Type: Review

References (274)

1. Hogan AR, Zhuge Y, Perez EA, Koniaris LG, Lew JI, Sola JE 2009 Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res 156:167-172
2. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
3. Farahati J, Parlowsky T, Mäder U, Reiners C, Bucsky P 1998 Differentiated thyroid cancer in children and adolescents. Langenbecks Arch Surg 383:235-239
4. Bleyer A, O'Leary M, Barr R, Ries LAG 2006 Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD: National Institutes of Health
5. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL 1998 Clinical features associated with metastasis and recurrence of differentiated thy-roid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 49:619-628
6. Reiners C, Demidchik YE 2003 Differentiated thyroid cancer in childhood: pathology, diagnosis, therapy. Pediatr Endocrinol Rev 1(Suppl 2):230-235; discussion 235-236
7. Chaukar DA, Rangarajan V, Nair N, Dcruz AK, Nadkarni MS, Pai PS, Mistry RC 2005 Pediatric thyroid cancer. J Surg Oncol 92:130-133
8. Okada T, Sasaki F, Takahashi H, Taguchi K, Takahashi M, Watanabe K, Itoh T, Ota S, Todo S 2006 Management of childhood and adolescent thyroid carcinoma: long-term follow-up and clinical characteristics. Eur J Pediatr Surg 16:8-13
9. Thompson GB, Hay ID 2004 Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 28:1187-1198
10. O'Gorman CS, Hamilton J, Rachmiel M, Gupta A, Ngan BY, Daneman D 2010 Thyroid cancer in childhood: a retrospective review of childhood course. Thyroid 20:375-380
11. Rachmiel M, Charron M, Gupta A, Hamilton J, Wherrett D, Forte V, Daneman D 2006 Evidence-based review of treatment and follow up of pediatric patients with differentiated thyroid carcinoma. J Pediatr Endocrinol Metab 19:1377-1393
12. Luster M, Lassmann M, Freudenberg LS, Reiners C 2007 Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones (Athens) 6:269-278
13. Dinauer C, Francis GL 2007 Thyroid cancer in children. Endocrinol Metab Clin North Am 36:779-806, vii
14. Dinauer CA, Breuer C, Rivkees SA 2008 Differentiated thyroid cancer in children: diagnosis and management. Curr Opin Oncol 20:59-65
15. Zimmerman D, Hay ID, Gough IR, Goellner JR, Ryan JJ, Grant CS, McConahey WM 1988 Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. Surgery 104:1157-1166
16. Zaydfudim V, Feurer ID, Griffin MR, Phay JE 2008 The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 144:1070-1077; discussion 1077-1078
17. Hung W, Sarlis NJ 2002 Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 12:683-702
18. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 83: 4116-4122
19. Shattuck TM, Westra WH, Ladenson PW, Arnold A 2005 Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med 352: 2406-2412
20. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
21. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
22. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M 1987 Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 65:1088-1094
23. Lazar L, Lebenthal Y, Steinmetz A, Yackobovitch-Gavan M, Phillip M 2009 Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr 154:708-714
24. Machens A, Lorenz K, Nguyen Thanh P, Brauckhoff M, Dralle H 2010 Papillary thyroid cancer in children and adolescents does not differ in growth pattern and metastatic behavior. J Pediatr 157:648-652
25. Powers PA, Dinauer CA, TuttleRM,Robie DK, McClellan DR, Francis GL 2003 Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 16:693-702
26. Brink JS, van Heerden JA, McIver B, Salomao DR, Farley DR, Grant CS, Thompson GB, Zimmerman D, Hay ID 2000 Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery 128:881-886; discussion 886-887
27. La Quaglia MP, Black T, Holcomb GW, 3rd, Sklar C, Azizkhan RG, Haase GM, Newman KD 2000 Differentiated thyroid cancer: clinical characteristics, treatment, and outcome in patients under 21 years of agewhopresent with distant metastases. A report from the Surgical Discipline Committee of the Children's Cancer Group. J Pediatr Surg 35:955-959; discussion 960
28. Duffy Jr BJ, Fitzgerald PJ 1950 Cancer of the thyroid in children: a report of twenty-eight cases. J Clin Endocrinol Metab 10:1296-1308
29. Winship T, Rosvoll RV 1961 A study of thyroid cancer in children. Am J Surg 102:747-752
30. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD 2005 Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365:2014-2023
31. Dolphin GW 1968 The risk of thyroid cancers following irradiation. Health Phys 15:219-228
32. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice Jr JD 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259-277
33. Preston DL,RonE, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K 2007 Solid cancer incidence in atomicbombsurvivors: 1958-1998. Radiat Res 168:1-64
34. Watanabe S, Shimosato Y, Okita T, Ezaki H, ShigemitsuT 1972 Leukemia and thyroid carcinoma found among Abomb survivors in Hiroshima. Recent Results Cancer Res 39:57-83
35. Davis S, Kopecky KJ, Hamilton TE, Onstad L 2004 Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA 292:2600-2613
36. Robbins J, Schneider AB 2000 Thyroid cancer following exposure to radioactive iodine. Rev Endocr Metab Disord 1:197-203
37. Gilbert ES, Huang L, Bouville A, Berg CD, Ron E 2010 Thyroid cancer rates and 131I doses from Nevada atmospheric nuclear bomb tests: an update. Radiat Res 173: 659-664
38. Memon A, Godward S, Williams D, Siddique I, Al-Saleh K 2010 Dental x-rays and the risk of thyroid cancer: a casecontrol study. ACTA Oncol 49:447-453
39. Reiners C, Demidchik YE, Drozd VM, Biko J 2008 Thyroid cancer in infants and adolescents after Chernobyl. Minerva Endocrinol 33:381-395
40. Baverstock K, Egloff B, Pinchera A, Ruchti C, Williams D 1992 Thyroid cancer after Chernobyl. Nature 359:21-22
41. Kazakov VS, Demidchik EP, Astakhova LN 1992 Thyroid cancer after Chernobyl. Nature 359:21
42. Ron E 2007 Thyroid cancer incidence among people living in areas contaminated by radiation from the Chernobyl accident. Health Phys 93:502-511
43. Demidchik YE, Saenko VA, Yamashita S 2007 Childhood thyroid cancer in Belarus, Russia, and Ukraine after Chernobyl and at present. Arq Bras Endocrinol Metabol 51: 748-762
44. Williams ED 2006 Chernobyl and thyroid cancer. J Surg Oncol 94:670-677
45. Sankila R, Garwicz S, Olsen JH, Döllner H, Hertz H, Kreuger A, Langmark F, Lanning M,Möller T, Tulinius H 1996 Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14:1442-1446
46. Davies SM 2007 Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. Pediatr Blood Cancer 48:727-730
47. Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pukkala E, Weiderpass E, Olsen JH, Tracey E, McBride ML,BrewsterDH,Pompe-Kirn V, Tonita JM, Kliewer EV, Chia KS, Jonasson JG, Martos C, Magnani C, Boffetta P 2008 Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. Eur J Cancer 44:830-839
48. Tucker MA, Jones PH, Boice Jr JD, Robison LL, Stone BJ, Stovall M, Jenkin RD, Lubin JH, Baum ES, Siegel SE 1991 Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 51:2885-2888
49. Brignardello E, Corrias A, Isolato G, Palestini N, Cordero di Montezemolo L, Fagioli F, Boccuzzi G 2008 Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J Clin Endocrinol Metab 93:4840-4843
50. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, Carli AF, Caruso G, Toti P, Capitani S, Pammolli A, Pacini F 2008 Familial nonmedullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer 15:1075-1081
51. Topliss D 2004 Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 60:18-20
52. Malchoff CD, Malchoff DM 2004 Familial papillary thyroid carcinoma. Cancer Treat Res 122:381-387
53. Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe Y, Hosoda Y 1988 Familial occurrence of differentiated, nonmedullary thyroid carcinoma. World J Surg 12:565-571
54. Körber C, Geling M, Werner E, Mörtl M, Mäder U, Reiners C, Farahati J 2000 [Incidence of familial non-medullary thyroid carcinoma in the patient register of the Clinic and Polyclinic of Nuclear Medicine, University of Wurzburg]. Nuklearmedizin 39:27-32 (German)
55. Hillenbrand A, Varhaug JE, Brauckhoff M, Pandev R, Haufe S, Dotzenrath C, Köberle R, Hoffmann R, Klein G, Kadmon M, Negele T, Hagieva T, Henne-Bruns D, Luster M, Weber T 2010 Familial nonmedullary thyroid carcinoma: clinical relevance and prognosis. A European multicenter study. Langenbecks Arch Surg 395:851-858
56. Parameswaran R, Brooks S, Sadler GP 2010 Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg 8:186-193
57. Morrison PJ, Atkinson AB 2009 Genetic aspects of familial thyroid cancer. Oncologist 14:571-577
58. Tran T, Gianoukakis AG 2010 Familial thyroid neoplasia: impact of technological advances on detection and monitoring. Curr Opin Endocrinol Diabetes Obes 17:425-431
59. Farooq A, Walker LJ, Bowling J, Audisio RA 2010 Cowden syndrome. Cancer Treat Rev 36:577-583
60. Blumenthal GM, Dennis PA 2008 PTEN hamartoma tumor syndromes. Eur J Hum Genet 16:1289-1300
61. Richards ML 2010 Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid 20:707-713
62. Smith JR, Marqusee E,WebbS, Nose V, Fishman SJ, Shamberger RC, Frates MC, Huang SA 2011 Thyroid nodules and cancer in children with PTEN hamartoma tumor syndrome. J Clin Endocrinology Metab 96:34-37
63. Vriens MR, Suh I, Moses W, Kebebew E 2009 Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 19:1343-1349
64. Half E, Bercovich D, Rozen P 2009 Familial adenomatous polyposis. Orphanet J Rare Dis 4:22
65. Perrier ND, van Heerden JA, Goellner JR, Williams ED, Gharib H, Marchesa P, Church JM, Fazio VW, LarsonDR 1998 Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 22:738-742; discussion 743
66. Krohn K, Paschke R 2001 Loss of heterozygocity at the thyroid peroxidase gene locus in solitary cold thyroid nodules. Thyroid 11:741-747
67. Rastogi M, Hanna C, Mandel S, LaFranchi S 2010 Congenital hypothyroidism associated with goiter: risk of thyroid nodules and cancer. Pediatr Res
68. Landry CS, Brock G, Scoggins CR, McMasters KM, Martin 2nd RC 2009 A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol 16:51-60
69. Vriens MR, Moses W, Weng J, Peng M, Griffin A, Bleyer A, Pollock BH, Indelicato DJ, Hwang J, Kebebew E 2011 Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer 117:259-267
70. Fenton C, Anderson J, Lukes Y, Dinauer CA, Tuttle RM, Francis GL 1999 Ras mutations are uncommon in sporadic thyroid cancer in children and young adults. J Endocrinol Invest 22:781-789
71. Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA 1996 Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 13:687-693
72. Suchy B, Waldmann V, Klugbauer S, Rabes HM 1998 Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 77:952-955
73. Yamashita S, Saenko V 2007 Mechanisms of disease: molecular genetics of childhood thyroid cancers. Nat Clin Pract Endocrinol Metab 3:422-429
74. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM 2000 The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85:1170-1175
75. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA 1996 Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009
76. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694
77. Nikiforov YE 2008 Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21(Suppl 2): S37-S43
78. Penko K, Livezey J, Fenton C, Patel A, Nicholson D, Flora M, Oakley K, Tuttle RM, Francis G 2005 BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15:320-325
79. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23:7436-7440
80. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93
81. Nikiforova MN, Nikiforov YE 2009 Molecular diagnostics and predictors in thyroid cancer. Thyroid 19:1351-1361
82. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762
83. Lima J, Trovisco V, Soares P, Máximo V, Magalha{ogonek}es J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simo{ogonek} es M 2004 BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4267-4271
84. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S 2004 Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4280-4284
85. Niedziela M 2006 Pathogenesis, diagnosis and management of thyroid nodules in children. Endocr Relat Cancer 13:427-453
86. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA 2008 Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 93:2173-2180
87. Corrias A, Einaudi S, Chiorboli E, Weber G, Crino' A, Andreo M, Cesaretti G, de Sanctis L, Messina MF, Segni M, Cicchetti M, Vigone M, Pasquino AM, Spera S, de Luca F, Mussa GC, Bona G 2001 Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab 86:4644-4648
88. Lyshchik A, Drozd V, Demidchik Y, Reiners C 2005 Diagnosis of thyroid cancer in children: value of gray-scale and power doppler US. Radiology 235:604-613
89. Moslavac S, Matesa N, Kusiæ Z 2010 Thyroid fine needle aspiration cytology in children and adolescents. Coll Antropol 34:197-200
90. Kapila K, Pathan SK, George SS, Haji BE, Das DK, Qadan LR 2010 Fine needle aspiration cytology of the thyroid in children and adolescents: experience with 792 aspirates. Acta Cytol 54:569-574
91. Corrias A, Mussa A, Baronio F, Arrigo T, Salerno M, Segni M, Vigone MC, Gastaldi R, Zirilli G, Tuli G, Beccaria L, Iughetti L, Einaudi S, Weber G, De Luca F, Cassio A 2010 Diagnostic features of thyroid nodules in pediatrics. Arch Pediatr Adolesc Med 164:714-719
92. Theoharis CG, Schofield KM, Hammers L, Udelsman R, Chhieng DC 2009 The Bethesda thyroid fine-needle aspiration classification system: year 1 at an academic institution. Thyroid 19:1215-1223
93. Mazzaferri EL, Sipos J 2008 Should all patients with subcentimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion? Thyroid 18:597-602
94. Izquierdo R, Shankar R, Kort K, Khurana K 2009 Ultrasound-guided fine-needle aspiration in the management of thyroid nodules in children and adolescents. Thyroid 19: 703-705
95. Leboulleux S, Baudin E, Hartl DW, Travagli JP, Schlumberger M 2004 Follicular-cell derived thyroid cancer in children. Eur J Cancer 40:1655-1659
96. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new american thyroid association staging system. Thyroid 20:1341-1349
97. Farahati J, Reiners C, Demidchik EP 1999 Is the UICC/ AJCC classification of primary tumor in childhood thyroid carcinoma valid? J Nucl Med 40:2125
98. Powers PA, Dinauer CA, Tuttle RM, Francis GL 2004 The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pediatr Endocrinol Metab 17:339-343
99. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S 2006 Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243:525-532
100. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wy-goda Z, Jarzab B 2007 Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48:879-888
101. Hay ID, Gonzalez-Losada T, Reinalda MS, Honetschlager JA, Richards ML, Thompson GB 2010 Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World J Surg 34:1192-1202
102. Canadian Pediatric Thyroid Nodule (CaPTN) Study Group 2008 The Canadian Pediatric Thyroid Nodule Study: an evaluation of current management practices. J Pediatr Surg 43:826-830
103. Silva F, Laguna R, Nieves-Rivera F 2010 Pediatric thyroid cancer with extensive disease in a Hispanic population: outcome and long-term survival. J Pediatr Endocrinol Metab 23:59-64
104. Haveman JW, van Tol KM, Rouwé CW, Piers DA, Plukker JT 2003 Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 10:15-20
105. Kowalski LP, Gonçalves Filho J, Pinto CA, Carvalho AL, de Camargo B 2003 Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg 129:746-749
106. Giuffrida D, Scollo C, Pellegriti G, Lavenia G, Iurato MP, Pezzin V, Belfiore A 2002 Differentiated thyroid cancer in children and adolescents. J Endocrinol Invest 25:18-24
107. Grigsby PW, Gal-or A, Michalski JM, Doherty GM 2002 Childhood and adolescent thyroid carcinoma. Cancer 95: 724-729
108. Ben Arush MW, Stein ME, Perez Nahum M, Zidan J, Kuten A 2000 Pediatric thyroid carcinoma: 22 years of experience at the Northern Israel Oncology Center (1973-1995). Pediatr Hematol Oncol 17:85-92
109. Jarzab B, Handkiewicz Junak D, Włoch J, Kalemba B, Roskosz J, Kukulska A, Puch Z 2000 Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 27:833-841
110. Landau D, Vini L, A'Hern R, Harmer C 2000 Thyroid cancer in children: the Royal Marsden Hospital experience. Eur J Cancer 36:214-220
111. Rybakov SJ, Komissarenko IV, Tronko ND, Kvachenyuk AN,Bogdanova TI, Kovalenko AE, Bolgov MY 2000 Thyroid cancer in children of Ukraine after the Chernobyl accident. World J Surg 24:1446-1449
112. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb 3rd GW, Sklar C, Vlamis V, Haase GM, La Quaglia MP 1998 Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. Ann Surg 227:533-541
113. Vassilopoulou-Sellin R, Goepfert H, Raney B, Schultz PN 1998 Differentiated thyroid cancer in children and adolescents: clinical outcome and mortality after long-term follow-up. Head Neck 20:549-555
114. Vassilopoulou-Sellin R, Schultz PN, Haynie TP 1996 Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78:493-501
115. Harness JK, Thompson NW, McLeod MK, Pasieka JL, Fukuuchi A 1992 Differentiated thyroid carcinoma in children and adolescents. World J Surg 16:547-553; discussion 553-554
116. Ceccarelli C, Pacini F, Lippi F, Elisei R, Arganini M, Miccoli P, Pinchera A 1988 Thyroid cancer in children and adolescents. Surgery 104:1143-1148
117. La Quaglia MP, Corbally MT, Heller G, Exelby PR, Brennan MF 1988 Recurrence and morbidity in differentiated thyroid carcinoma in children. Surgery 104:1149-1156
118. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL 1999 Extensive surgery improves recurrencefree survival for children and young patients with class I papillary thyroid carcinoma. J Pediatr Surg 34:1799-1804
119. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack Jr BC, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R 2009 Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19:1153-1158
120. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134: 946-954; discussion 954-955
121. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin 3rd GL 2004 Surgeon-performed ultrasound in the management of thyroid malignancy.AmSurg 70:576-580; discussion 580-582
122. Gonzá lez HE, Cruz F, O'Brien A, Goñi I, León A, Claure R, Camus M, Dominguez F, Mosso L, Arteaga E, Gonzá lez G, Ló pez JM, Rodriguez JA, Carrasco C, Fardella C 2007 Impact of preoperative ultrasonographic staging of the neck in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133:1258-1262
123. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, Reading CC, Charboneau JW 2006 Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141:489-494; discussion 494-496
124. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H 1990 Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 160:341-343
125. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, Cangir A, Haynie TP 1993 Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 71:1348-1352
126. Wada N, Sugino K, Mimura T, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K, Nakayama H, Hirakawa S, Rino Y, Masuda M, Ito K 2009 Pediatric differentiated thyroid carcinoma in stage I: risk factor analysis for disease free survival. BMC Cancer 9:306
127. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
128. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T 1998 Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol 29:4-10
129. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK 2009 Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 193:871-878
130. Gimm O, Rath FW, Dralle H 1998 Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg 85: 252-254
131. Bonnet S, Hartl DM, Travagli JP 2010 Lymph node dissection for thyroid cancer. J Visc Surg 147:e155-e159
132. Machens A, Hauptmann S, Dralle H 2009 Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery 145:176-181
133. Udelsman R, Lakatos E, Ladenson P 1996 Optimal surgery for papillary thyroid carcinoma. World J Surg 20:88-93
134. Udelsman R 2000 Thyroid cancer surgery. Rev Endocr Metab Disord 1:155-163
135. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511-518
136. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C 2007 Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375-381; discussion 381-384
137. Borson-Chazot F, Causeret S, Lifante JC, Augros M, Berger N, Peix JL 2004 Predictive factors for recurrence from a series of 74 children and adolescents with differentiated thyroid cancer. World J Surg 28:1088-1092
138. Miller BS, Doherty GM 2011 An examination of recently revised differentiated thyroid cancer guidelines. Curr Opin Oncol 23:1-6
139. Mazzaferri EL 2009 A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab 94:1086-1088
140. Doherty GM 2009 Prophylactic central lymph node dissection: continued controversy. Oncology (Williston Park) 23:603, 608
141. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, Chami L, Schlumberger M, Travagli JP 2009 Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94:1162-1167
142. Machens A, Hinze R, Thomusch O, Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22-28
143. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A, Sancho JJ, Sitges-Serra A 2005 Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 138:1095-1100, discussion 1100-1101
144. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058-3065
145. Shindo M, Stern A 2010 Total thyroidectomy with and without selective central compartment dissection: a comparison of complication rates. Arch Otolaryngol Head Neck Surg 136:584-587
146. Giles Y, Boztepe H, Terzioglu T, Tezelman S 2004 The advantage of total thyroidectomy to avoid reoperation for incidental thyroid cancer in multinodular goiter. Arch Surg 139:179-182
147. Seidlin SM, Oshry E, Yalow AA 1948 Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma; a preliminary report. J Clin Endocrinol Metab 8:423-432
148. Coliez R, Tubiana M, Dutreix J, Guelfi J 1951 Results of examination of 85 cases of cancer of the thyroid with radioactive iodine. J Radiol Electrol Arch Electr Medicale 32:881-895 (Undetermined Language)
149. Beierwaltes WH 1978 The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79-94
150. Van Nostrand D 2009 The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 19:1381-1391
151. Van Nostrand D, Wartofsky L 2007 Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 36:807-822, vii-viii
152. Bal CS, Kumar A, Chandra P, Dwivedi SN, Pant GS 2006 A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy. ACTA Oncol 45:1067-1072
153. Maxon HR 1999 Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43:313-323
154. Maxon 3rd HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD 1992 Radioiodine-131 therapy for well-differentiated thyroid cancer: a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33: 1132-1136
155. Maxon 3rd HR, Smith HS 1990 Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin NorthAm19:685-718
156. Beierwaltes WH 1987 Radioiodine therapy of thyroid disease. Int J Rad Appl Instrum B 14:177-181
157. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967
158. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S 1984 An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 25: 1287-1293
159. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937-941
160. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171-182
161. Robbins RJ, Schlumberger MJ 2005 The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S-37S
162. Beierwaltes WH 1979 The history of the use of radioactive iodine. Semin Nucl Med 9:151-155
163. Leeper RD 1985 Thyroid cancer. Med Clin North Am 69: 1079-1096
164. Medvedec M 2005 Thyroid stunning in vivo and in vitro. Nucl Med Commun 26:731-735
165. Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M 2010 Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37:896-903
166. Beierwaltes WH, Johnson PC 1956 Thyroid carcinoma treated with radioactive iodine; an eight-year experience. J Mich State Med Soc 55:410-419
167. Van Nostrand D, Neutze J, Atkins F 1986 Side effects of "rational dose" iodine-131 therapy for metastatic welldifferentiated thyroid carcinoma. J Nucl Med 27:1519-1527
168. Leeper RD 1973 The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 36:1143-1152
169. Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees S, Reiners C, Hänscheid H 2011 I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab 96:E1268-E1271
170. Kulkarni K, Van Nostrand D, Atkins F, Aiken M, Burman K, Wartofsky L 2006 The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16:1019-1023
171. Van Nostrand D, Atkins F, Moreau S, Aiken M, Kulkarni K, Wu JS, Burman KD, Wartofsky L 2009 Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroid 19: 1093-1098
172. Rall JE, Alpers JB, LewallenCG,SonenbergM,BermanM, Rawson RW 1957 Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 17:1263-1276
173. Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, Wahl RL, Sgouros G 2006 Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 47:1985-1994
174. Sgouros G, Song H, Ladenson PW, Wahl RL 2006 Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med 47:1977-1984
175. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, Robeson WR, Larson SM 1996 Quantitative imaging of iodine-124 with PET. J Nucl Med 37:1557-1562
176. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM, Besenfelder H, Bares R 2002 Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29:760-767
177. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366-1372
178. Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C 2009 Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 16: 1283-1289
179. Bal CS, Kumar A, Pant GS 2004 Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 89:1666-1673
180. Mazzaferri EL 2009 What is the optimal initial treatment of low-risk papillary thyroid cancer (and why is it controversial)? Oncology (Williston Park) 23:579-588
181. Machens A, Holzhausen HJ, Lautenschläger C, Thanh PN, Dralle H 2003 Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer 98:712-719
182. Mazzaferri EL 2006Howbeneficial is radioiodine therapy for treating distant metastases from thyroid carcinoma? Nat Clin Pract Endocrinol Metab 2:610-611
183. Mazzaferri EL 2007 Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498-512
184. Puxeddu E, Filetti S 2009 The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice. Thyroid 19: 1145-1147
185. Hindié E, Mellie'reD, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, Lange J, Perlemuter L, Askienazy S 2003 Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 30:974-981
186. Bal CS, Kumar A, Chandra P, Dwivedi SN, Mukhopadhyaya S 2004 Is chest x-ray or high-resolution computed tomography scan of the chest sufficient investigation to detect pulmonary metastasis in pediatric differentiated thyroid cancer? Thyroid 14:217-225
187. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899
188. Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V 2010 Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. Eur J Nucl MedMol Imaging 38:1269 -1302
189. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651-659
190. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin NorthAm 37:457-480, x
191. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676
192. Schneider AB, Viana MA, Ron E 2009 Weighing shadows: can meta-analysis help define the risk-benefit ratio of RAI treatment for low-risk thyroid cancer patients? Thyroid 19:435-436
193. Mallick U, Harmer C, Clarke S, Moss L, Nicol A, Clarke P, Smellie J, McCready R, Farnell K, Franklyn J, John R, Nutting C,YapB,LemonC, Wadlsey J, Gerrard G, Roques T, Macias E, Whitaker S, Abdul-Hamid A, Alvarez P, Kadalayil L, Hackshaw A HiLo: multicentre randomised phase III clinical trials of high vs low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation for differentiated thyroid cancer. Program of the 14th International Thyroid Congress, Paris, France, 2010
194. Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Rousseau A, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Benhamou E, Schlumberger M Comparison of four strategies of radioiodine ablation in patients with thyroid cancer with low-risk recurrence: the randomized, prospective ESTIMABL study on 753 patients. Program of the 14th International Thyroid Conference, Paris, France, 2010
195. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, LadensonPW,Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19:1043-1048
196. Bernet V 2010 Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 95: 3586-3592
197. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H 1994 Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18:559-567; discussion 567-568
198. Dralle H, Machens A 2008 Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab 22:971-987
199. Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J 1991 Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133-147
200. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723-5729
201. Samuel AM, Rajashekharrao B, Shah DH 1998 Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 39:1531-1536
202. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L 1997 Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 38:669-675
203. Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, Tong CC, Wong IS, Lau WH 2002 Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52:784-795
204. Collini P, Mattavelli F, Spinelli C, Massimino M 2007 Treatment of sporadic nonmedullary thyroid carcinomas in pediatric age. Expert Rev Anticancer Ther 7:23-30
205. Pazaitou-Panayiotou K, Kaprara A, Boudina M, Georgiou E, Drimonitis A, Vainas I, Raptou E, Galaktidou G 2005 Thyroid carcinoma in children and adolescents: presentation, clinical course, and outcome of therapy in 23 children and adolescents in Northern Greece. Hormones (Athens) 4:213-220
206. Lazarus JH 1995 Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 29:464-469
207. Pawelczak M, David R, Franklin B, Kessler M, Lam L, Shah B 2010 Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review.Thyroid 20:1095-1101
208. ChowSM,LawSC, MendenhallWM,AuSK,YauS,Mang O, Lau WH 2004 Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 42:176-183
209. Parisi MT, Mankoff D 2007 Differentiated pediatric thyroid cancer: correlates with adult disease, controversies in treatment. Semin Nucl Med 37:340-356
210. Kalemba B, Rozkosz J, Włoch J, Jarzab B 1998 [Early results of 131I therapy of differentiated thyroid carcinoma in children]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 4:27-35 (Polish)
211. Wakeford R 2004 The cancer epidemiology of radiation. Oncogene 23:6404-6428
212. Preston RJ 2004 Children as a sensitive subpopulation for the risk assessment process. Toxicol Appl Pharmacol 199: 132-141
213. Ron E 2002 Ionizing radiation and cancer risk: evidence from epidemiology. Pediatr Radiol 32:232-237; discussion 242-244
214. Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P 2007 Treatment outcome of Graves' disease in Thai children. J Med Assoc Thai 90:1815-1820
215. Van Savell Jr H, Hughes SM, Bower C, Parham DM 2004 Lymphocytic infiltration in pediatric thyroid carcinomas. Pediatr Dev Pathol 7:487-492
216. Bal C, Padhy AK, Jana S, Pant GS, Basu AK 1996 Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574-2580
217. Huang SC, Wu VC, Lin SY, Sheu WH, Song YM, Lin YH, Wu CC, Chang WD 2009 Factors related to clinical hypothyroid severity in thyroid cancer patients after thyroid hormone withdrawal. Thyroid 19:13-20
218. Edmonds CJ, Hayes S, Kermode JC, Thompson BD 1977 Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 50:799-807
219. Caldwell KL, Jones R, Hollowell JG 2005 Urinary iodine concentration: United States National Health And Nutrition Examination Survey 2001-2002. Thyroid 15:692-699
220. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS 2010 Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 20:173-179
221. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654
222. Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, Bournaud C, Gupta S, Schlumberger M, RicardM 2008 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445-1450
223. Iorcansky S, Herzovich V, Qualey RR, Tuttle RM 2005 Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 90:6553-6555
224. Luster M, Handkiewicz-Junak D, Grossi A, Zacharin M, Taïeb D, Cruz O, Hitzel A, Casas JA, Mäder U, Dottorini ME 2009 Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. J Clin Endocrinol Metab 94: 3948-3953
225. Hall P, Mattsson A, Boice Jr JD 1996 Thyroid cancer after diagnostic administration of iodine-131. Radiat Res 145: 86-92
226. Zanzonico PB 2007 Lack of increased cancer risks associated with radioiodine therapy of hyperthyroidism. NCRP Report 80
227. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P 2007 Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109:1972-1979
228. Rivkees SA 2006 The treatment of Graves' disease in children. J Pediatr Endocrinol Metab 19:1095-1111
229. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P 1999 Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353:2111-2115
230. Ron E, DoodyMM,Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice Jr JD 1998 Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280:347-355
231. Hall P, Berg G, Bjelkengren G, Boice JD Jr, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Tennvall J, WiklundK 1992 Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer 50:886-890
232. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG, et al. 1991 Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 83:1072-1077
233. Ronckers CM, McCarron P, Ron E 2005 Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281-288
234. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515
235. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 22 March 2011 Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 10.1002/cncr.26070
236. Verkooijen RB, Smit JW, Romijn JA, Stokkel MP 2006 The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155:801-806
237. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644
238. Garsi JP, Rubino C, Lonn S, Schvartz C, Andruccioli M, Bardet S, Henry-Amar M, Le Thai F, Hall P, Ricard M, Schlumberger HG, De Vathaire F 2010 Impact of radioidone treatmetn on the risk of second primary malignancy (SPM) following thyroid cancer:AEuropean cohort study. Program of the 14th Annual International Thyroid Conference, Paris, France, 2010
239. Zanzonico PB 1997 Radiation dose to patients and relatives incident to 131I therapy. Thyroid 7:199-204
240. Howell RW, Wessels BW, Loevinger R, Watson EE, Bolch WE, Brill AB, Charkes ND, Fisher DR, Hays MT, Robertson JS, Siegel JA, Thomas SR 1999 The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med 40:3S-10S
241. Garsi JP, Schlumberger M, Ricard M, Labbe M, Ceccarelli C, Schvartz C, Henry-Amar M, Bardet S, Rubino C, de Vathaire F 2009 Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clin Endocrinol (Oxf) 71:880-883
242. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbé M, Ceccarelli C, Schvartz C, Henri-Amar M, Bardet S, de Vathaire F 2008 Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 49:845-852
243. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C 1996 Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-612
244. Bal C, Kumar A, Tripathi M, Chandrashekar N, Phom H, Murali NR, Chandra P, Pant GS 2005 High-dose radioiodine treatment for differentiated thyroid carcinoma is not associated with change in female fertility or any genetic risk to the offspring. Int J Radiat Oncol Biol Phys 63:449-455
245. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ 1976 Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17: 460-464
246. Krassas GE, Pontikides N 2005 Gonadal effect of radiation from 131I in male patients with thyroid carcinoma. Arch Androl 51:171-175
247. Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A 2010 The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging. Eur J Nucl Med Mol Imaging 37:2298-2306
248. Barrington SF, KettleAG,O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ 1996 Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 23:123-130
249. Grigsby PW, Siegel BA, Baker S, Eichling JO 2000 Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. JAMA 283:2272-2274
250. The American Thyroid Association (ATA), The Endocrine Society (TES), the Society of Nuclear Medicine (SNM), the American Association of Clinical Endocrinologists (AACE) 2010 Joint statement on radioactive precautions following radioactive iodine therapy. October 20, 2010. http://www.thyroid.org/professionals/publications/documents/Radioactive_Iodine_Statement.pdf
251. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon 3rd HR 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744
252. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH 1992 Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344-350
253. Batrinos ML 2006 The problem of exogenous subclinical hyperthyroidism. Hormones (Athens) 5:119-125
254. Osman F, Gammage MD, Franklyn JA 2002 Hyperthyroidism and cardiovascular morbidity and mortality. Thyroid 12:483-487
255. Rivkees SA 2010 Pediatric Graves' Disease: Controversies in Management. Horm Res Paediatr 74:305-311
256. Biondi B, Cooper DS 2010 Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 20:135-146
257. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1:32-40
258. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111
259. Verburg FA, Stokkel MP,Dü ren C, Verkooijen RB,Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M 2010 No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J NuclMedMolImaging 37:276-283
260. Sherry NA, Levitsky LL 2008 Management of diabetic ketoacidosis in children and adolescents. Paediatr Drugs 10: 209-215
261. Costello I, Wong IC, Nunn AJ 2004 A literature review to identify interventions to improve the use of medicines in children. Child Care Health Dev 30:647-665
262. Falkenstein K, Flynn L, Kirkpatrick B, Casa-Melley A, Dunn S 2004 Non-compliance in children post-liver transplant. Whoare the culprits? Pediatr Transplant 8:233-236
263. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM 1993 Primary non-compliance with prescribed medication in primary care. BMJ 307: 846-848
264. Beck-Peccoz P, Persani L, LaFranchi S 2004 Safety of medications and hormones used in the treatment of pediatric thyroid disorders. Pediatr Endocrinol Rev 2(Suppl 1):124-133
265. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J 2010 Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20:587-595
266. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for lowrisk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441
267. Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B 1992 Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 33:1478-1480
268. Bournaud C, Charrié A, Nozie'res C, Chikh K, Lapras V, Denier ML, Paulin C, Decaussin-Petrucci M, Peix JL, Lifante JC, Cornu C, Giraud C, Orgiazzi J, Borson-Chazot F 2010 Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method. Clin Chem Lab Med 48:1171-1177
269. Kim MJ, Kim EK, Kim BM, Kwak JY, Lee EJ, Park CS, Cheong WY, Nam KH 2009 Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf) 70:145-151
270. Chao M 2010 Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan. Clin Oncol (R Coll Radiol) 22:438-447
271. Heston TF, Wahl RL 2010 Molecular imaging in thyroid cancer. Cancer Imaging 10:1-7
272. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241-5248
273. Pace L, Nicolai E, Klain M, Salvatore M 2009 Diagnostic value ofFDGPET/CTimaging.QJ NuclMedMolImaging 53:503-512
274. Finkelstein SE, GrigsbyPW,Siegel BA, Dehdashti F, Moley JF, Hall BL 2008 Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 15:286-292